Biotech

All Articles

Sanofi's tolebrutinib fails 2 of 3 late-stage MS trials

.Sanofi is actually still bented on taking its own a number of sclerosis (MS) med tolebrutinib to th...

Galapagos' stock up as fund presents intent to mold its progression

.Galapagos is actually happening under additional pressure coming from real estate investors. Having...

Cell- concentrated Sana scoops very first CSO-- Chutes &amp Ladders

.Welcome to recently's Chutes &amp Ladders, our summary of notable management hirings, firings and a...

Allist pays off Jacobio $21M, landing duty in Chinese KRAS race

.Shanghai Allist Pharmaceuticals has purchased on its own a starring job in China's KRAS market, pay...

ReNeuron leaving AIM exchange after skipping fundraising target

.ReNeuron has participated in the long list of biotechs to leave behind Greater london's objective s...

MBX files for IPO to take opposition to Ascendis into phase 3

.MBX Biosciences has included in the latest flurry of IPO filings. The biotech, which filed its own ...

FDA grows probe into Lykos' MDMA tests: WSJ

.For Lykos Therapeutics and the company's prospective MDMA-assisted treatment for post-traumatic str...

Gene publisher Volume giving up 131 employees

.Simply days after gene publisher Tome Biosciences declared undisclosed operational cuts, a more cle...

Repare lays off 25% of workers as biotech stops preclinical R&ampD

.Repare Therapeutics is actually giving up a quarter of its workforce as the oncology biotech scales...

J &amp J declare FDA approval of $6.5 B autoimmune drug

.Johnson &amp Johnson has taken yet another step towards realizing a return on its $6.5 billion nipo...